Combining osimertinib with chemotherapy improved progression-free survival in EGFR-mutated non-small cell lung cancer, new interim data show, but experts have raised concerns about toxicity.
A new interim analysis finds more evidence that ibrutinib plus rituximab is a viable option for younger patients with untreated chronic lymphocytic leukemia compared with standard chemoimmunotherapy.
The relapse rate among patients with relapsing-remitting multiple sclerosis who were treated with rituximab was higher than among those treated with ocrelizumab, results of a noninferiority study suggest.